Techcyte's digital diagnostics platform applies the latest in convolutional neural networks to assist ARUP's staff in delivering fast and accurate results to doctors and patients.
The platform supports a range of whole slide scanners as well as multiple tests, such as blood differential, cervical cytology, fine needle aspiration, ova and parasites (fecal), urinalysis, and bacteriology.
The collaboration between ARUP and Techcyte will significantly accelerate the number of new test algorithms available to the lab diagnostic market.
ARUP's vast expertise and access to rare samples combined with Techcyte's data-pipeline and machine-learning experts will produce high-quality algorithms that can be developed quickly and then introduced into the market following thorough testing.
Medical labs, hardware manufacturers, hospitals, and clinics will all benefit from Techcyte's solutions. In 2019, Techcyte will deliver solutions for blood analysis, fecal ova and parasites, cervical cytology and bacteriology. Additional tests will be announced when they are ready for market use.
Headquartered in Orem, Utah, Techcyte, Inc. was founded in 2013 as a technology transfer from the University of Utah with a mission to lower healthcare costs through artificial intelligence.
Techcyte uses the power of deep machine learning to perform image analysis of whole slide images. Image analysis is required for widespread adoption of digital pathology in research, pharma, human, air quality and veterinary diagnostic testing.
ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development.
A nonprofit enterprise of the University of Utah, ARUP offers an extensive test menu of highly complex and unique medical tests.
Rather than competing with its clients for physician office business, ARUP chooses instead to support clients' existing test menus by offering highly complex and unique lab tests, with accompanying consultative support, to enhance their abilities to provide laboratory services.
INOVIO's INO-3107 Biologics License Application accepted by US FDA
ABL Bio receives upfront payment and equity investment from Eli Lilly
CARsgen Therapeutics submits two IND applications for CT0596 to Chinese regulator
Repare Therapeutics sells RP-3467 asset to Gilead Sciences for up to USD30m
Sanofi agrees USD2.2bn acquisition of Dynavax to strengthen adult vaccine portfolio
Sanofi and Regeneron's Dupixent gains Japan approval for paediatric asthma patients aged 6 to 11
Aqualung Therapeutics' Phase 2a lung fibrosis study approved by US FDA
NeuroSense Therapeutics completes safety evaluation of PrimeC in Alzheimer's Phase 2 study
BrioHealth Solutions enrols 100th participant in BrioVAD System trial
Faron launches BLAZE trial with Institute of Cancer Research to address immunotherapy resistance
AstraZeneca secures US Breakthrough status for Enhertu in early breast cancer
Ipsen licenses Simcere Zaiming antibody-drug conjugate for global development
Shield Therapeutics wins FDA approval to expand ACCRUFeR use to adolescents